What should I do if I experience breakthrough bleeding on GLP-1 therapy
Semaglutide at 2.4 mg has also been associated with a 20% reduction in the risk of heart attack or stroke in non-diabetic patients with obesity or overweight with existing cardiovascular conditions (Lincoff et al., 2023)
Amylin Is Making a Comeback: Why This Forgotten Hormone Is Back in the Spotlight 3 weeks ago Articles, Diabetes, GLP- 1 Agonist Therapy Center, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,580 views For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment
Low-density lipoprotein cholesterol (LDL-C) reductions are more modest, generally in the range of 2-10%, though some patients experience more substantial decreases
The IGF-1/AKT pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by AKT
Her new book, "Enough: Your Health, Your Weight, and What It's Like to Be Free," cowritten with Jastreboff, is part diary, part guidebook to navigating the new world of GLP-1 drugs for obesity and diabetes
